BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

The National Institute for Health and Care Excellence (NICE) has recommended sparsentan (Filspari, Vifor Pharma) for treating primary immunoglobulin A nephropathy in adults. The recommendation ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more quickly on sparsentan (Filspari) than irbesartan (Avapro ...

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

SAN DIEGO, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX), presented new data further demonstrating the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy ...

for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on sparsentan for treating primary IgA nephropathy and submitted it to NICE. The FDG ...

First non-immunosuppressive dual-action therapy approved for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

The two-year results from the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically meaningful benefit at 108 weeks with significant ...